中国神经再生研究(英文版) ›› 2014, Vol. 9 ›› Issue (13): 1316-1322.doi: 10.4103/1673-5374.137580

• 综述:脑损伤修复保护与再生 • 上一篇    下一篇

脑卒中靶向溶栓治疗的神经保护效应

  

  • 收稿日期:2014-05-12 出版日期:2014-07-11 发布日期:2014-07-11

Targeted thrombolysis strategies for neuroprotective effect

Junping Zhang, Guoxing Ma, Zhimin Lv, Yu Zhou, Chunguang Wen, Yaqing Wu, Ruian Xu   

  1. School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
  • Received:2014-05-12 Online:2014-07-11 Published:2014-07-11
  • Contact: Ruian Xu, Ph.D., School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molcelaur Medicine, Ministry of Education, No. 902, Fanhua Science Building, 668 Jimei Avenue, Jimei District, Xiamen 362021, Fujian Province, China, hmmedu@hqu.edu.cn.
  • Supported by:

    This study was supported by the National Natural Science Foundation of China, No. 81271692.

摘要:

溶栓剂已广泛用于脑卒中的治疗,其延长治疗时间窗的作用也引起了关注,由于药非靶向治疗,因此在治疗中常会出现一些副作用,如出现系统性纤维蛋白原溶解和出血等。为了提高溶栓剂治疗脑卒中的有效性、安全性、特异性和提高其神经保护效应,近年许多研究者将目光投向靶向溶栓剂。文章综述了针对栓块不同成分的靶向溶栓剂用于脑卒中治疗的研究进展,以期为最大程度发挥脑卒中溶栓治疗的神经保护作用提供参考。

关键词: 神经再生, 溶栓剂, 靶向溶栓, 纤溶系统, 脑卒中, 脑梗死, 神经保护, 靶向纤维蛋白, 靶向血小板, 靶向红细胞, 综述

Abstract:

Stroke is usually treated by systemic thrombolytic therapy if the patient presents within an appropriate time window. There is also widespread interest in the development of thrombolytic agents that can be used in cases of delayed presentation. Current agents that can be used in cases of delayed presentation of nerve damage by thrombus. Current systemic thrombolytic therapy is associated with adverse effects such as fibrinogenolysis and bleeding. In an attempt to increase the efficacy, safety, and specificity of thrombolytic therapy, a number of targeted thrombolytic agents have been studied in recent years. This review focuses on the concepts underlying targeted thrombolytic therapy and describes recent drug developments in this field.

Key words: nerve regeneration, review, thrombolytic agent, fibrinolytic system, stroke, cerebrovascular disease, neuroprotective drug, fibrinolytic mechanism, fibrin targeting, platelet targeting, red blood cell targeting, cerebral hemorrhage, NSFC grant, neural regeneration